

London Genetics to present at BioTrinity 2010

London, UK, 12 April 2010 – London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, will be presenting a business and partnering update on April 13 at the BioTrinity 2010¹ conference. The conference, one of the UK biotech sector's leading partnering and investor meetings, provides an excellent opportunity for the company to discuss with potential collaborators how pharmacogenetics can add value to their drug development.

The London Genetics presentation will feature at 4.40pm in the 'From Concept to Patient – Biotechnology' Company Showcase. In her presentation 'Harnessing Pharmacogenetics – Partnering with Biotech and Pharma', CEO Dominique Kleyn will describe the company's consultancy, collaboration and development business model, and recent progress such as the first awards from its proof-of-concept fund.

Commenting on the conference, Dominique Kleyn said 'London Genetics is delighted to be presenting at BioTrinity 2010. We are in a busy partnering phase and are in discussion with several companies on how we can add value to their drug development programmes via pharmacogenetics. The biopharmaceutical industry is increasingly realising the potential of this approach in helping it meet the myriad of challenges and opportunities it faces, from lack of R&D productivity to the need to show cost-effectiveness.'

¹ BioTrinity 2010 is being held on April 12-14 at Newbury Racecourse, Newbury, Berkshire, UK. For more details, please go to <http://www.biotrinity.com/silverstripe/>

For further information or to meet us at conferences please contact:

London Genetics Ltd

BioIncubator Unit
Imperial College
Prince Consort Road
South Kensington
London SW7 2BP

Dominique Kleyn CEO

T + 44 (0)20 7594 1838

Emma Palmer Foster

Strategic Communications Consultant

T + 44 (0)7880 787 185

E communications@londongenetics.com



Notes to Editors:

About London Genetics

London Genetics Limited, a not-for-profit company, is an expert in the use of pharmacogenetics in clinical drug discovery and development. Established in 2007 with funding from the London Development Agency, its seven founding partners are leading London academic and medical institutions with clinical and genetic expertise and significant patient resources.

The company provides pharmaceutical and biotechnology companies with access to this expertise and resource, as well as providing strategic advice on the application of pharmacogenetics for successful drug development. LGL has broad therapeutic expertise with a focus on cardiovascular disease and drug side-effects of a cardiovascular nature. Recent agreements developed by London Genetics include a collaboration between the International Serious Adverse Events Consortium, St George's University of London and the Drug Safety Research Unit at Southampton, UK. The parties are working on genetic markers for drug-induced cardiac arrhythmia. LGL is based at the Imperial College Incubator in London, and has ISO 9001 accreditation.

For further information, please go to www.londongeneticslimited.com

About pharmacogenetics

Genetic differences between individuals mean that drug response rates are often variable across a population, and this has significant implications for healthcare cost effectiveness. Pharmacogenetics, the study of the clinical consequences of genetic differences in the way people metabolise and respond to drugs, is expected to generate better understanding of how drugs work in the body, and therefore give insight into how to develop more efficacious and safer drugs.

It also has implications for product life cycle management and the revitalisation of drugs which previously failed in clinical trials. With drug development costs rising and R&D productivity falling, plus increased regulator focus on safety and cost-effectiveness, pharmacogenetics is expected to become increasingly important in drug development. The FDA and the EMEA have recognised this in their Critical Path Initiative and Road Map respectively.